Work

Author response: SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance

Year: 2021

Type: peer-review

Abstract: A genetic discovery screen for epigenetic factors accelerating melanoma development in vivo identifies SATB2 as a driver of tumor invasion and resistance to FDA-approved BRAF-targeted inhibitor Vemurafenib.

DOI: 10.7554/elife.64370.sa2

Authors: Maurizio Fazio, Ellen van Rooijen, Michelle Dang, Glenn van de Hoek, Julien Ablain, Jeffrey K Mito, Song Yang, Andrew Thomas, Jonathan Michael, Tania Fabo, Rodsy Modhurima, Patrizia Pessina, Charles K Kaufman, Yi Zhou, Richard M White, Leonard I Zon

Institutions: Boston Children's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Brigham and Women's Hospital, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W3132083106

Cites:

Cited by: 1

Related to: 10